Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: IMAGENT

« Back to Dashboard
Imagent is a drug marketed by Imcor Pharms Co and Alliance Pharm and is included in two NDAs. There are three patents protecting this drug.

This drug has thirty-two patent family members in eighteen countries.

The generic ingredient in IMAGENT is perflubron. Additional details are available on the perflubron profile page.

Summary for Tradename: IMAGENT

Patents:3
Applicants:2
NDAs:2

Clinical Trials for: IMAGENT

Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.
Status: Completed Condition: Asthma

Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression
Status: Recruiting Condition: Major Depression

Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma
Status: Recruiting Condition: Asthma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 2002DISCNNo5,695,741<disabled> <disabled>
Alliance Pharm
IMAGENT
perflubron
LIQUID;ORAL020091-001Aug 13, 1993DISCNNo<disabled><disabled>
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 2002DISCNNo5,798,091<disabled> <disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: IMAGENT

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 20025,605,673<disabled>
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 20026,280,705<disabled>
Imcor Pharms Co
IMAGENT
dimyristoyl lecithin; perflexane
INJECTABLE;INTRAVENOUS021191-001May 31, 20026,280,704<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Premature patent expiration for: IMAGENT

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
5,798,091
IMAGENT
August 25, 2010
5,720,938
IMAGENT
February 24, 2010

International Patent Family for Tradename: IMAGENT

Country Document Number Publication Date
Hong Kong1013403Mar 24, 2006
Germany69434119Nov 03, 2005
European Patent Office0812214Dec 17, 1997
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc